Case Report: Recurrent uterine inflammatory myofibroblastic tumor harboring IGFBP5-ALK fusion with sustained response to iruplinalkib - Takeaways - MDSpire

Case Report: Recurrent uterine inflammatory myofibroblastic tumor harboring IGFBP5-ALK fusion with sustained response to iruplinalkib

  • By

  • Ke Zhao

  • Min Hu

  • Runfeng Yang

  • Yi Huang

  • June 12, 2026

  • 0 min

Share

  • 1

    Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor, often misdiagnosed, with ALK gene rearrangements in about 50% of cases.

  • 2

    A 58-year-old woman with recurrent uterine IMT was initially misdiagnosed as having uterine myxoid leiomyoma and later leiomyosarcoma.

  • 3

    The patient achieved complete response to the second-generation ALK-TKI, iruplinalkib, after resistance to the first-generation inhibitor, crizotinib.

  • 4

    This case is the first to report therapeutic success of iruplinalkib in uterine IMT, suggesting a sequential ALK-TKI treatment strategy.

  • 5

    Imaging surveillance indicated no disease progression for over 15 months after the patient achieved complete response with iruplinalkib.

Original Source(s)

Case Report: Recurrent uterine inflammatory myofibroblastic tumor harboring IGFBP5-ALK fusion with sustained response to iruplinalkib

  • by Ke Zhao, Min Hu, Runfeng Yang, Yi Huang

  • June 12, 2026

Related Content

Why CAR T cell therapy fails in renal cell carcinoma

Correction: Risk stratification for adjuvant radiotherapy in pathologic T3N0 rectal cancer using a DeepSurv-based survival model

Fine needle assisted puncture positioning technique for CT-guided percutaneous interventions